Clinical and vaccination characteristics of the patient cohort
| Sex . | N . | % . |
|---|---|---|
| Female | 14 | 50 |
| Male | 14 | 50 |
| Age (y) | ||
| Median (range) | 63 | 23-78 |
| Race | ||
| White | 21 | 75 |
| Other | 7 | 25 |
| Lymphoma subtype | ||
| CLL/SLL | 10 | 35.7 |
| Non-Hodgkin Lymphoma (all subtypes) | 18 | 65.3 |
| DLBCL | 5 | 17.9 |
| FL | 3 | 10.7 |
| MZL | 5 | 17.9 |
| Other∗ | 5 | 17.9 |
| Vaccine maker | ||
| Pfizer | 15 | 53.6 |
| Moderna | 11 | 39.3 |
| No vaccine | 2 | 7.1 |
| Number of vaccine doses - median (range) | ||
| Pfizer | 3 | 2-4 |
| Moderna | 3 | 2-5 |
| Follow-up after Evusheld (d) | ||
| Median (range) | 42 | (4-131) |
| Prior anti-CD20 therapy | ||
| Yes | 12 | 42.9 |
| No | 16 | 57.1 |
| Prior cytotoxic chemotherapy | ||
| Yes | 22 | 78.6 |
| No | 6 | 21.4 |
| Prior cellular therapy | ||
| Yes† | 2 | 7.1 |
| No | 26 | 92.9 |
| Ongoing Bcl-2 inhibitor therapy | ||
| Yes | 5 | 17.9 |
| No | 23 | 82.1 |
| Ongoing BTK inhibitor therapy | ||
| Yes | 3 | 10.7 |
| No | 25 | 89.2 |
| Sex . | N . | % . |
|---|---|---|
| Female | 14 | 50 |
| Male | 14 | 50 |
| Age (y) | ||
| Median (range) | 63 | 23-78 |
| Race | ||
| White | 21 | 75 |
| Other | 7 | 25 |
| Lymphoma subtype | ||
| CLL/SLL | 10 | 35.7 |
| Non-Hodgkin Lymphoma (all subtypes) | 18 | 65.3 |
| DLBCL | 5 | 17.9 |
| FL | 3 | 10.7 |
| MZL | 5 | 17.9 |
| Other∗ | 5 | 17.9 |
| Vaccine maker | ||
| Pfizer | 15 | 53.6 |
| Moderna | 11 | 39.3 |
| No vaccine | 2 | 7.1 |
| Number of vaccine doses - median (range) | ||
| Pfizer | 3 | 2-4 |
| Moderna | 3 | 2-5 |
| Follow-up after Evusheld (d) | ||
| Median (range) | 42 | (4-131) |
| Prior anti-CD20 therapy | ||
| Yes | 12 | 42.9 |
| No | 16 | 57.1 |
| Prior cytotoxic chemotherapy | ||
| Yes | 22 | 78.6 |
| No | 6 | 21.4 |
| Prior cellular therapy | ||
| Yes† | 2 | 7.1 |
| No | 26 | 92.9 |
| Ongoing Bcl-2 inhibitor therapy | ||
| Yes | 5 | 17.9 |
| No | 23 | 82.1 |
| Ongoing BTK inhibitor therapy | ||
| Yes | 3 | 10.7 |
| No | 25 | 89.2 |
BTK, Bruton's tyrosine kinase; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma.
Includes (N): Burkitt's (1), Peripheral T-cell Lymphoma (PTCL) (1), Primary effusion lymphoma (PEL) (1), Hairy cell (1), B-cell not otherwise specified (NOS) (1)
Two patients received anti-CD19 chimeric antigen receptor T-cell therapy; no other cell therapies were used.